Search Results - "MURUA ESCOBAR, Hugo"

Refine Results
  1. 1

    The Comparative Oncology of Canine Malignant Melanoma in Targeted Therapy: A Systematic Review of In Vitro Experiments and Animal Model Reports by He, Xiaohui, Gao, Yu, Deng, Yuqing, He, Junying, Nolte, Ingo, Murua Escobar, Hugo, Yu, Feng

    “…Canine malignant melanoma (CMM) is highly aggressive and mostly located in the oral cavity. CMM is the predominant type of canine oral malignancy and shows…”
    Get full text
    Journal Article
  2. 2

    Transfer learning of clinical outcomes from preclinical molecular data, principles and perspectives by Kowald, Axel, Barrantes, Israel, Möller, Steffen, Palmer, Daniel, Murua Escobar, Hugo, Schwerk, Anne, Fuellen, Georg

    Published in Briefings in bioinformatics (13-05-2022)
    “…Abstract Accurate transfer learning of clinical outcomes from one cellular context to another, between cell types, developmental stages, omics modalities or…”
    Get full text
    Journal Article
  3. 3

    Genomic heterogeneity in primary colorectal carcinomas and their metastases: born bad or brought up a villain? by Hühns, Maja, Krohn, Saskia, Murua Escobar, Hugo, Prall, Friedrich

    Published in Human pathology (01-04-2018)
    “…Progression of solid cancers, colorectal carcinomas among them, from their primaries to metastatic lesions traditionally is thought to proceed by a stepwise…”
    Get full text
    Journal Article
  4. 4

    Gold nanoparticle mediated laser transfection for efficient siRNA mediated gene knock down by Heinemann, Dag, Schomaker, Markus, Kalies, Stefan, Schieck, Maximilian, Carlson, Regina, Murua Escobar, Hugo, Ripken, Tammo, Meyer, Heiko, Heisterkamp, Alexander

    Published in PloS one (11-03-2013)
    “…Laser based transfection methods have proven to be an efficient and gentle alternative to established molecule delivery methods like lipofection or…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Comparative Analyses of Targeted Myeloid Cancer Next-Generation Sequencing Panel in Fresh Blood, Bone Marrow and FFPE Material by Hobeck, Andrea Daniela, Wendt, Sophia, Krohn, Saskia, Knuebel, Gudrun, Bartels, Stephan, Schipper, Elisa, Junghanss, Christian, Murua Escobar, Hugo

    “…Next-generation sequencing is a vital tool for personalized diagnostics and therapies in cancer. Despite numerous advantages, the method depends on multiple…”
    Get full text
    Journal Article
  7. 7

    MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines by Packeiser, Eva-Maria, Engels, Leoni, Nolte, Ingo, Goericke-Pesch, Sandra, Murua Escobar, Hugo

    “…Acquired chemoresistance during chemotherapy, often accompanied by cross- and multi-resistance, limits therapeutic outcomes and leads to recurrence. In order…”
    Get full text
    Journal Article
  8. 8

    Intramolecular Base-Free Catalytic Wittig Reaction: Synthesis of Benzoxepinones by Grandane, Aiga, Longwitz, Lars, Roolf, Catrin, Spannenberg, Anke, Murua Escobar, Hugo, Junghanss, Christian, Suna, Edgars, Werner, Thomas

    Published in Journal of organic chemistry (01-02-2019)
    “…A straightforward two-step synthesis of benzoxepinones was developed via base-free phosphane-catalyzed Wittig reaction. 3-Methyl-1-phenyl-2-phospholene 1-oxide…”
    Get full text
    Journal Article
  9. 9

    Multicohort study testing the generalisability of the SASKit-ML stroke and PDAC prognostic model pipeline to other chronic diseases by Palmer, Daniel, Henze, Larissa, Murua Escobar, Hugo, Walter, Uwe, Kowald, Axel, Fuellen, Georg

    Published in BMJ open (30-09-2024)
    “…ObjectivesTo validate and test the generalisability of the SASKit-ML pipeline, a prepublished feature selection and machine learning pipeline for the…”
    Get full text
    Journal Article
  10. 10

    Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A -Rearranged Acute B-Lymphoblastic Leukemia Cells by Holz, Clemens, Lange, Sandra, Sekora, Anett, Knuebel, Gudrun, Krohn, Saskia, Murua Escobar, Hugo, Junghanss, Christian, Richter, Anna

    “…Numerous hematologic neoplasms, including acute B-lymphoblastic leukemia (B-ALL), are characterized by overexpression of anti-apoptotic BCL-2 family proteins…”
    Get full text
    Journal Article
  11. 11

    Alterations in Tumor Aggression Following Androgen Receptor Signaling Restoration in Canine Prostate Cancer Cell Lines by Vasilatis, Demitria M, Batra, Neelu, Lucchesi, Christopher A, Abria, Christine J, Packeiser, Eva-Maria, Murua Escobar, Hugo, Ghosh, Paramita M

    “…In prostate cancer (PCa), androgens upregulate tumorigenesis, whereas in benign tissue, the revival of androgen receptor (AR) signaling suppresses aggressive…”
    Get full text
    Journal Article
  12. 12

    Role of miRNA Let-7 and Its Major Targets in Prostate Cancer by Nolte, Ingo, Murua Escobar, Hugo, Ngezahayo, Anaclet, Wagner, S.

    Published in BioMed research international (01-01-2014)
    “…Prostate cancer is worldwide the sixth leading cause of cancer related death in men thus early detection and successful treatment are still of major interest…”
    Get full text
    Journal Article
  13. 13

    Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis by Packeiser, Eva-Maria, Hewicker-Trautwein, Marion, Thiemeyer, Heike, Mohr, Annika, Junginger, Johannes, Schille, Jan Torben, Murua Escobar, Hugo, Nolte, Ingo

    Published in PloS one (13-03-2020)
    “…Canine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) of prostate and urinary bladder are highly invasive and metastatic tumors of closely…”
    Get full text
    Journal Article
  14. 14

    Validation of an LC-MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma by Schwarz, Rico, Richter, Anna, Ito, Elisabeth R D, Murua Escobar, Hugo, Junghanß, Christian, Hinz, Burkhard

    Published in Molecules (Basel, Switzerland) (07-04-2022)
    “…Silmitasertib (CX-4945) is currently being investigated in clinical trials against various types of cancer. The U.S. Food and Drug Administration (FDA) has…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    SLM produced porous titanium implant improvements for enhanced vascularization and osteoblast seeding by Matena, Julia, Petersen, Svea, Gieseke, Matthias, Kampmann, Andreas, Teske, Michael, Beyerbach, Martin, Murua Escobar, Hugo, Haferkamp, Heinz, Gellrich, Nils-Claudius, Nolte, Ingo

    “…To improve well-known titanium implants, pores can be used for increasing bone formation and close bone-implant interface. Selective Laser Melting (SLM)…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer by Schulz, Benjamin, Leitner, Emily, Schreiber, Tim, Lindner, Tobias, Schwarz, Rico, Aboutara, Nadine, Ma, Yixuan, Escobar, Hugo Murua, Palme, Rupert, Hinz, Burkhard, Vollmar, Brigitte, Zechner, Dietmar

    Published in Cancers (16-05-2024)
    “…Preclinical studies rarely test the efficacy of therapies in both sexes. The field of oncology is no exception in this regard. In a model of syngeneic,…”
    Get full text
    Journal Article